Clinical Trial

Efficacy Ultrasound-guided Genicular Nerve Radiofrequency Treatment

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 2, 2024 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Radiofrequency (RF) application is a treatment method that temporarily blocks pain transmission in the nerve where the application is made, through the heat emitted by radio waves. Genicular nerve ablation with RF has recently become a promising treatment option for the treatment of chronic knee pain. These methods are based on the principle that interfering with the sensory nerve fibers of a painful structure can relieve pain and restore function. Their targets are sensory nerves located on the periosteum before entering the knee joint capsule. The knee joint is innervated by a complex nerve network called genicular nerves, which are articular branches of many nerves such as the femoral, tibial, peroneal, saphenous and obturator nerves. Some of the genicular nerves can be easily localized. The intermedius genicular nerve carries the sensation of subpatellar pain. The intermedius genicular nerve is located under the vastus intermedius muscle, anterior to the distal femoral shaft, just above the bony cortex. Targeting sensory nerves in addition to standard procedures and improving target identification using ultrasound guidance may increase treatment success. The aim of this study is to investigate the effect of ultrasound-guided genicular nerve radiofrequency therapy on pain and knee function by targeting only the traditional 3 genicular nerves and the intermedius genicular nerve in addition to the traditional genicular nerves in advanced gonarthrosis patients with prominent anterior knee pain.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-27.
Trial Details
NCT Number NCT06479642
Lead Sponsor Yunus Burak Bayır
Conditions Gonarthrosis
Enrollment 72 participants
Start Date 2024-09-01
Primary Completion 2025-09-01 (estimated)
Study Completion 2025-09-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-02